Clinical Trial Update: A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components

View source ↗

Summary

A completed open-label treatment-use study evaluating patient safety after transfusion of INTERCEPT platelet components.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus
• Dengue Virus

Drugs mentioned

• INTERCEPT platelet components (INTERCEPT platelet components)

Snippet

Sponsor: Cerus Corporation | Conditions: Chikungunya Virus, Dengue Virus | Status: COMPLETED | Results posted: 2018-10-30